Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Transplant Cell Ther. 2021 Jan 7;27(3):262.e1–262.e11. doi: 10.1016/j.jtct.2021.01.004

Table 2.

Incidence of hospital-acquired bloodstream infections by chlorhexidine gluconate usage

High (>75%)
N=25		 Medium (50-75%)
N=33		 Low (<50%)
N=45		 None (0%)
N=89		 P-value1
Clinically-Significant BSI2
 No. of Infections (%) 2 (8%) 5 (15.2%) 7 (15.6%) 27 (30.3%) 0.003
 Incidence Rate (no./1000 patient-days) 3.58 6.44 6.67 12.70
LCBI3
 No. of Infections (%) 1 (4%) 5 (15.2%) 6 (13.3%) 20 (22.5%) 0.03
 Incidence Rate (no./1000 patient-days) 1.79 6.44 5.72 9.28
CLABSI4
 No. of Infections (%) 1 (4%) 5 (15.2%) 6 (13.3%) 19 (21.3%) 0.040
 Incidence Rate (no./1000 patient-days) 1.79 6.44 5.72 9.30
MBI-LCBI5
 No. of Infections (%) 0 (0%) 1 (3%) 4 (8.9%) 16 (18%) 0.002
 Incidence Rate (no./1000 patient-days) 0.00 1.29 3.81 7.81
1

P-values obtained via the Cochran-Armitage linear trend test.

2

Clinically-Significant BSI: clinically-significant bloodstream infection.

3

LCBI: laboratory-confirmed bloodstream infection.

4

CLABSI: central line-associated bloodstream infection.

5

MBI-LCBI: mucosal barrier injury laboratory-confirmed bloodstream infection.